4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0001209191-21-004466
Chief Executive Officer sold 20,000 shares at an average $213.67 ($4,273,311)
- Chief Executive Officer acquired 20,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kulkarni Samarth Chief Executive Officer | 2021-01-15 | Option exercise | +20,000 | $1.81 | $36,200 | 202,989 | D |
| Kulkarni Samarth Chief Executive Officer | 2021-01-15 | Sale | −3,140 | $211.83 | $665,146 | 199,849 | D |
| Kulkarni Samarth Chief Executive Officer | 2021-01-15 | Sale | −6,525 | $212.75 | $1,388,194 | 193,324 | D |
| Kulkarni Samarth Chief Executive Officer | 2021-01-15 | Sale | −5,623 | $213.71 | $1,201,691 | 187,701 | D |
| Kulkarni Samarth Chief Executive Officer | 2021-01-15 | Sale | −1,700 | $214.68 | $364,956 | 186,001 | D |
| Kulkarni Samarth Chief Executive Officer | 2021-01-15 | Sale | −1,708 | $216.50 | $369,782 | 184,293 | D |
| Kulkarni Samarth Chief Executive Officer | 2021-01-15 | Sale | −1,304 | $217.44 | $283,542 | 182,989 | D |
| Derivatives | |||||||
| Kulkarni Samarth Chief Executive Officer | 2021-01-15 | Option exercise · Stock Option (Right to Buy) | −20,000 | 108,983 | D | ||
| Open-market sales · 20,000 sh · avg $213.67 · $4,273,311 | |||||||
Loading xslF345X03/doc4.xml…